IV ketamine for Boca Raton — psychiatry-supervised, integrated with therapy.

For Boca Raton clients, RECO Health's Delray Beach campus is 20 minutes north on Federal Highway — close enough that a six-session ketamine induction runs alongside work and family rather than replacing them. The program is psychiatry-supervised, uses 0.5 mg/kg IV racemic ketamine over 40 minutes with continuous vital monitoring and CADSS assessment, and pairs each infusion with a next-day integration therapy session. Both IV ketamine and Spravato are offered, so insurance coverage and clinical fit — not availability — drive the choice.

From Mizner Park or Royal Palm Place, RECO Health’s Delray Beach campus is a 20-minute drive north on Federal Highway — 11 miles, shorter than most morning commutes, and short enough that a psychiatry-supervised ketamine therapy protocol fits inside daily life instead of requiring a temporary relocation. Boca Raton clients drive to the infusion appointment, complete the 40-minute session with monitored recovery, are driven home, and return the following day for an integration session — a schedule that supports employment, family, and outpatient continuity rather than interrupting them.

How ketamine works, and why response is measured in days rather than weeks

Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. The downstream cascade — increased AMPA receptor throughput, brain-derived neurotrophic factor (BDNF) release, and synaptogenesis in prefrontal cortex — is a fundamentally different mechanism than monoamine reuptake inhibition, and it is the reason clinical response appears on a different timescale. An SSRI such as sertraline or escitalopram gradually re-tunes serotonergic signaling; measurable improvement on the PHQ-9 typically requires four to six weeks. Ketamine’s antidepressant and anti-suicidal effect emerges within hours to days.

That speed is why ketamine belongs in the treatment-resistant depression pathway and in the acute-crisis pathway. It is not a first-line agent — SSRIs, SNRIs, augmentation with aripiprazole or lithium, and adequate psychotherapy trials remain the initial standard. But when a patient has failed two or more adequate trials, or when suicidal ideation is active and six weeks is not a clinically available window, ketamine’s rapid mechanism is what changes the risk calculus. At RECO Health it is used in that specific role: a psychiatry-supervised medical intervention for treatment-resistant depression, refractory PTSD, and acute suicidality — not a general wellness offering.

The 40-minute infusion, monitored recovery, and the six-session induction

Each infusion appointment runs roughly two hours end-to-end. Intake includes vital signs and a brief PHQ-9 and C-SSRS check to trend response and safety across the series. The infusion itself is 0.5 mg/kg racemic ketamine delivered intravenously over 40 minutes, weight-adjusted and occasionally titrated based on prior-session response and tolerability. Blood pressure, heart rate, and oxygen saturation are monitored continuously by clinical staff; transient hypertension is expected and managed on protocol. Dissociative experience is assessed with the Clinician-Administered Dissociative States Scale (CADSS).

Recovery is 30 to 60 minutes of monitored observation in a low-stimulus setting until the patient is ambulatory, oriented, and stable to discharge. Because residual dissociation and psychomotor effects preclude driving for the remainder of the day, clients are driven home — Boca Raton patients typically arrange a family member, partner, or ride-share. The induction series is six infusions across two to three weeks. That interval is where sustained response either consolidates or does not, and it is the window in which the psychiatrist decides whether to continue, extend, or transition to maintenance boosters scheduled by response duration.

Integration with psychotherapy is what makes response durable

Ketamine opens a window; therapy determines whether the client walks through it. RECO’s protocol pairs the infusion series with integration sessions — typically the day after each infusion — where a therapist works with the material that surfaced during the session and consolidates the cognitive and emotional shifts into lasting change. The modality depends on presentation: Cognitive Behavioral Therapy for entrenched depressive cognitions, Acceptance and Commitment Therapy for values-based re-engagement, EMDR for trauma content that emerges during infusion, and Motivational Interviewing where ambivalence about recovery is part of the picture.

The published literature is consistent on this point. Ketamine without integration produces shorter response duration and higher relapse rates than ketamine paired with structured psychotherapy. Isolated infusions can produce a rapid mood lift that fades within one to two weeks; integrated protocols extend response and, in a subset of patients, produce durable remission. Integration is not an add-on at RECO — it is the reason the program exists as a psychiatric service rather than an infusion suite.

IV ketamine versus Spravato, and how the choice is made

IV racemic ketamine is off-label for depression and is typically cash-pay. Spravato (esketamine) is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation, delivered intranasally under a Risk Evaluation and Mitigation Strategy (REMS) protocol and covered by most commercial insurance. The choice between them is clinical and financial rather than one being categorically superior.

Spravato tends to be the right choice when insurance coverage is the deciding factor and a twice-weekly-for-four-weeks induction, followed by weekly then biweekly maintenance, fits the patient’s schedule. IV ketamine tends to be the right choice when precise dose flexibility, response quality reported by the patient in prior trials, or a more compressed induction is clinically indicated. RECO Health offers both. The decision is made with the client during the psychiatry consult after reviewing prior antidepressant trials, comorbidities (hypertension, cardiovascular disease, substance use history), and insurance benefits.

What to expect on the first visit

The first visit is a psychiatric evaluation, not an infusion. The psychiatrist reviews prior medication trials at adequate dose and duration — commonly SSRIs, SNRIs, bupropion, and augmentation with aripiprazole, quetiapine, or lithium — along with prior psychotherapy and any history of TMS or ECT. Standardized measures are administered: PHQ-9 for depressive severity, GAD-7 for co-occurring anxiety, C-SSRS for suicidality, and where relevant the YBOCS or ASRS. Baseline vitals and an ECG where cardiovascular history warrants are completed before the first infusion is scheduled.

If IV ketamine or Spravato is indicated, the first infusion is typically scheduled within a week. Patients continue their other psychiatric medications unless a specific interaction requires adjustment; benzodiazepines and lamotrigine may blunt response and are discussed individually. The integration therapist is introduced during the same intake so the therapeutic relationship is established before the first session, not after.

Insurance and getting to Delray from Boca Raton

The Delray Beach campus is 11 miles north of downtown Boca Raton — roughly 20 minutes on Federal Highway or I-95, longer during season. Highland Beach, Boca West, and Downtown Boca clients typically drive; many coordinate ride-share for infusion days because of the post-session driving restriction. RECO Health works with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans on the psychiatric and Spravato side. Spravato is billed through medical benefits under the REMS pathway; IV ketamine is generally self-pay, and admissions provides a written cost estimate and can discuss whether Spravato is the more workable pathway before treatment begins.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.